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The analysis of patient blood transcriptional profiles
offers a means to investigate the immunological
mechanisms relevant to human diseases on a ge-
nome-wide scale. In addition, such studies provide a
basis for the discovery of clinically relevant biomarker
signatures. We designed a strategy for microarray
analysis that is based on the identification of tran-
scriptional modules formed by genes coordinately
expressed in multiple disease data sets. Mapping
changes in geneexpressionat themodule level gener-
ated disease-specific transcriptional fingerprints that
provide a stable framework for the visualization and
functional interpretation of microarray data. These
transcriptional modules were used as a basis for the
selection of biomarkers and the development of a
multivariate transcriptional indicator of disease pro-
gression in patients with systemic lupus erythemato-
sus. Thus, this work describes the implementation
andapplicationof amethodologydesigned tosupport
systems-scale analysis of the human immune system
in translational research settings.
INTRODUCTION
Patient-based microarray transcriptional studies aim to discover
biomarkers and to identify novel biological knowledge that will
unravel the mechanisms of disease pathogenesis. However,
these goals are met with considerable challenges. The use of
gene expression microarrays in clinical research has led to the
establishment of biomarker signatures from the analysis of both
tumor tissues (Alizadeh et al., 2000; Bittner et al., 2000; Golub150 Immunity 29, 150–164, July 18, 2008 ª2008 Elsevier Inc.et al., 1999) and blood samples (Allantaz et al., 2007; Baechler
et al., 2003; Bennett et al., 2003; Burczynski et al., 2005; Chaus-
sabel et al., 2005; Cobb et al., 2005; Kaizer et al., 2007; Ramilo
et al., 2007; Thach et al., 2005). Yet, questions have been raised
regarding the value of this approach for the discovery of stable
disease markers (Michiels et al., 2005). Among the concerns is
the fact that results of microarray analyses are prone to include
noise (i.e., false-positive results—see Ioannidis, 2005) and do not
compare well between laboratories and/or platforms (Bammler
et al., 2005; Hyatt et al., 2006; Irizarry et al., 2005; Jarvinen
et al., 2004; Larkin et al., 2005; Shi et al., 2006).
Leveraging patient transcriptional profiles as a means to iden-
tify relevant immunological mechanisms is also proving to be
a challenge. In fact, both microarray and patient-based studies
are considered by immunologists as fundamentally descriptive:
in the case of microarray studies, this is because the results of
system-wide screens do not conform to the reductionist knowl-
edge-discovery model prevailing in the field (Benoist et al.,
2006); in the case of patient-based studies, it is because the
means of testing hypotheses in order to prove a mechanism
are de facto very limited (Steinman and Mellman, 2004). Yet,
carrying out such studies in patients, at a systems level, is nec-
essary to advance immunological knowledge accumulated from
the study of model organisms (Benoist et al., 2006; Steinman and
Mellman, 2004).
Indeed, as technology platforms for systems-wide analysis
become more sophisticated and more accessible than ever be-
fore, it is essential to continue exploring novel strategies for the
exploitation of large-scale data. Among those, approaches to
uncover the modular organization and function of transcriptional
systems have already shown promise (Mootha et al., 2003; Rho-
des et al., 2005; Segal et al., 2004; reviewed in Segal et al., 2005).
Indeed, such analyses can transform our perception of large-
scale transcriptional studies beyond the level of individual genes
or lists of genes.
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Modular Analysis Framework for Blood GenomicsThe present work describes the implementation of a unique
approach for the analysis of blood microarray transcriptional
profiles, based on a modular data mining strategy. We showed
that this approach could improve our understanding of disease
pathogenesis and provide a basis for the selection of clinically
relevant transcriptional biomarkers.
RESULTS
Construction of Peripheral-Blood Mononuclear Cell
(PBMC) Transcriptional Modules
Comparing transcriptional profiles of two or more study groups
generates long lists of differentially expressed genes. Because
of the large number of comparisons performed (usually >
10,000), these results are permissive to noise, which in turn
can affect biomarker discovery and data interpretation (Ioanni-
dis, 2005; Michiels et al., 2005).
In order to circumvent these hurdles, we focused the analysis
on small sets of coordinately expressed transcripts. Indeed, the
probability for multiple transcripts to follow a complex pattern of
expression across dozens or hundreds of conditions only by
chance is low, and such sets of genes should therefore consti-
tute coherent and biologically meaningful transcriptional units.
Thus, we designed an algorithm for constructing sets of coordi-
nately expressed transcripts (i.e., modules) from PBMC microar-
ray profiles generated from a wide range of diseases. This stable
modular framework was then used as a basis for the analysis of
a separate PBMC data set.
The algorithm used for the construction of transcriptional
modules is described in detail in the Experimental Procedures
section (Figure S1, available online). In brief, the first step of
the module-construction process analyzes expression patterns
of transcripts across samples for individual diseases: sets of
coordinately expressed transcripts were identified with an un-
supervised clustering algorithm; in this case, the GeneSpring
Version 7.1 (Agilent) implementation of the K-Means algorithm
(k = 30). All transcripts detected in at least one sample were
used as input; no screening for differential expression was per-
formed. The second step of the module-construction process
analyzed the ‘‘clustering behavior’’ of transcripts across dis-
eases, taking into account the possibility that genes may
cocluster in some diseases but not in others. Also, in our exam-
ple, the transcripts that clustered together across all eight
diseases were grouped to form a set of modules (round 1 of se-
lection), and the stringency of the analysis was then decreased
gradually to identify transcripts that belong to a similar K-means
cluster in only a subset of diseases (round 2: seven out of eight
diseases; round 3: six out of eight diseases). This analysis of
gene-cluster membership across diseases relates to ‘‘graph
theory,’’ which is used in the mathematics and computer-
science fields to model pairwise relations between objects
(Biggs, 1986). It is important to note that the module-selection
process is ‘‘data-driven’’ and does not involve manual selection
of genes by the investigator.
We implemented the module-construction strategy described
above, using as input a total of 239 peripheral-blood mononu-
clear cell (PBMC) samples obtained from individuals with one
of the following conditions: systemic juvenile idiopathic arthritis
(n = 47), systemic lupus erythematosus (n = 40), type I diabetes(n = 20), metastatic melanoma (n = 39), acute infections (Escher-
ichia coli [n = 22], Staphylococcus aureus [n = 18], Influenza A
[n = 16]) or liver-transplant recipients undergoing immunosup-
pressive therapy (n = 37). Transcriptional profiles were generated
with Affymetrix U133A and U133B GeneChips (> 44,000 probe
sets). A total of 4742 transcripts, distributed among 28 sets,
were selected after running of the module-construction algo-
rithm described above (Figure S1; a complete list is provided in
Table S1). Each module is assigned a unique identifier indicating
the round and order of selection (i.e., M3.1 is the first module
identified in the third round of selection).
The stringency of this algorithm was tested statistically by
implementation of the same module-construction procedure
after randomization of the original data set. This process was re-
peated 200 times, without a single module identified (See Sup-
plemental Experimental Procedures for details). Therefore, the
analysis of gene-cluster membership across multiple diseases
provided a stringent means to identify PBMC transcriptional
modules.
The next step consists of functional characterization of each
module. Keyword occurrence in PubMed abstracts associated
with the genes within each module were analyzed by literature
profiling (Chaussabel and Sher, 2002). Differences in patterns
of keyword occurrence across modules were observed as illus-
trated in Figure S2, and functional associations were identified
for each of the 28 PBMC transcriptional modules (Table 1). Of
28 PBMC modules, 14 could be clearly linked with pathways
or cell types involved in immune processes (as detailed below).
Functional associations were also observed in the remaining
14 modules. M2.5, for example, includes genes encoding im-
mune-related molecules—CD40, CD80, CXCL12, IFNA5,
IL4R—as well as cytoskeleton-related molecules—Myosin, Ded-
icator of Cytokenesis, Syndecan 2, Plexin C1, Distrobrevin (see
Table 1 for details). Thus, transcriptional modules form coherent
transcriptional and functional units.
Using Modules to Map Transcriptional
Changes in Health and Disease
After identifying sets of coordinately expressed PBMC tran-
scripts on the basis of the analysis of patterns found in a wide
range of diseases, we used this modular framework as a stable
basis for analyzing individual PBMC data sets.
Modules were conceived as a stable framework for the analy-
sis of data generated independently of the sets that were initially
used for module construction. We analyzed PBMC microarray
transcriptional profiles generated from 14 patients with acute
Streptococcus pneumoniae infection and from ten age- and
sex-matched healthy control subjects. This data set was not
used in the module-selection process. Statistical comparisons
between patient and healthy control groups were performed
independently on a module-by-module basis (Mann-Whitney
rank test, p < 0.05). The transcriptional profiles of differentially
expressed genes were then represented on a graph for individual
modules (Figure 1A). The pie chart indicates the proportion of dif-
ferentially expressed transcripts for a given module (e.g., 49%
of the 322 transcripts forming module M3.2 were overexpressed
in patients with acute S. pneumoniae infection compared to
healthy controls). As shown in Figure 1A, differentially expressed
genes in each module were either predominantly overexpressedImmunity 29, 150–164, July 18, 2008 ª2008 Elsevier Inc. 151
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Modular Analysis Framework for Blood GenomicsTable 1. Functional Interpretation of Transcriptional Modules
Module I.D.
Number of
Probe Sets Keyword Selection Interpretation
M 1.1 76 Ig, Immunoglobulin,
Bone, Marrow, PreB,
IgM,Mu.
Plasma cells. Includes genes coding for Immunoglobulin
chains (e.g., IGHM, IGJ, IGLL1, IGKC, IGHD) and the plasma
cell marker CD38.
M 1.2 130 Platelet, Adhesion,
Aggregation,
Endothelial,
Vascular
Platelets. Includes genes coding for platelet glycoproteins
(ITGA2B, ITGB3, GP6, GP1A/B) and platelet-derived immune
mediators such as PPPB (pro-platelet basic protein) and PF4
(platelet factor 4).
M 1.3 80 Immunoreceptor,
BCR, B cell, IgG
B cells. Includes genes coding for B cell surface markers
(CD72, CD79A/B, CD19, CD22) and other B cell-associated
molecules: early B cell factor (EBF), B cell linker (BLNK), and B
lymphoid tyrosine kinase (BLK).
M 1.4 132 Replication,
Repression, Repair,
CREB, Lymphoid,
TNF-alpha
Undetermined. This set includes genes encoding regulators
and targets of the cAMP-signaling pathway (JUND, ATF4,
CREM, PDE4, NR4A2, VIL2) and repressors of TNF-alpha
mediated NF-KB activation (CYLD, ASK, TNFAIP3).
M 1.5 142 Monocytes,
Dendritic, MHC,
Costimulatory, TLR4,
MYD88
Myeloid lineage. Includes genes encoding molecules
expressed by cells of the myeloid lineage (CD86, CD163,
FCGR2A), some of which are involved in pathogen recognition
(CD14, TLR2, MYD88). This set also includes TNF-family
members (TNFR2, BAFF).
M 1.6 141 Zinc, Finger, P53,
RAS
Undetermined. This set includes genes coding for signaling
molecules; e.g., the zinc-finger-containing inhibitor of
activated STAT (PIAS1 and PIAS2) or the nuclear factor of
activated T cells, NFATC3.
M 1.7 129 Ribosome,
Translational, 40S,
60S, HLA
MHC/Ribosomal proteins. Almost exclusively formed by
genes encoding MHC class I molecules (HLA-A,B,C,G,E)+
Beta 2-microglobulin (B2M) or ribosomal proteins (RPLs,
RPSs).
M 1.8 154 Metabolism,
Biosynthesis,
Replication, Helicase
Undetermined. Includes genes encoding metabolic enzymes
(GLS, NSF1, NAT1) and factors involved in DNA replication
(PURA, TERF2, EIF2S1).
M 2.1 95 NK, Killer, Cytolytic,
CD8, Cell-mediated,
T cell,
CTL, IFN-g
Cytotoxic cells. Includes genes encoding cytotoxic T cells and
NK cell-surface markers (CD8A, CD2, CD160, NKG7, KLRs),
cytolytic molecules (granzyme, perforin, granulysin),
chemokines (CCL5, XCL1), and CTL/NK cell-associated
molecules (CTSW).
M 2.2 49 Granulocytes,
Neutrophils, Defense,
Myeloid,
Marrow
Neutrophils. This set includes genes encoding innate
molecules that are found in neutrophil granules
(lactotransferrin: LTF, defensin: DEAF1, bacterial permeability
increasing protein: BPI, cathelicidin antimicrobial protein:
CAMP.).
M 2.3 148 Erythrocytes, Red,
Anemia, Globin,
Hemoglobin
Erythrocytes. Includes hemoglobin genes (HGBs) and other
erythrocyte-associated genes (erythrocytic alkirin: ANK1,
glycophorin C: GYPC, hydroxymethylbilane synthase: HMBS,
erythroid-associated factor: ERAF).
M 2.4 133 Ribonucleoprotein,
60S, Nucleolus,
Assembly, Elongation
Ribosomal proteins. Includes genes encoding ribosomal
proteins (RPLs, RPSs), Eukaryotic Translation Elongation
Factor–family members (EEFs), and Nucleolar proteins
(NPM1, NOAL2, NAP1L1).
M 2.5 315 Adenoma, Interstitial,
Mesenchyme,
Dendrite,
Motor
Undetermined. This module includes genes encoding
immune-related molecules (CD40, CD80, CXCL12, IFNA5,
IL4R) as well as cytoskeleton-related molecules (Myosin,
Dedicator of Cytokinesis, Syndecan 2, Plexin C1, Distrobrevin).
M 2.6 165 Granulocytes,
Monocytes, Myeloid,
ERK,
Necrosis
Myeloid lineage. Includes genes expressed in myeloid-lineage
cells (IGTB2/CD18, Lymphotoxin beta receptor, Myeloid
related proteins 8/14 Formyl peptide receptor 1) such as
Monocytes and Neutrophils.152 Immunity 29, 150–164, July 18, 2008 ª2008 Elsevier Inc.
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Module I.D.
Number of
Probe Sets Keyword Selection Interpretation
M 2.7 71 No keywords
extracted.
Undetermined. This module is largely composed of transcripts
with no known function. Only 20 genes associated with
literature, including a member of the chemokine-like factor
superfamily (CKLFSF8).
M 2.8 141 Lymphoma, T cell,
CD4, CD8, TCR,
Thymus, Lymphoid,
IL2
T cells. Includes genes encoding T cell surface markers (CD5,
CD6, CD7, CD26, CD28, CD96) and molecules expressed by
lymphoid lineage cells (lymphotoxin beta, IL2-inducible T cell
kinase, TCF7, T cell differentiation protein mal, GATA3,
STAT5B).
M 2.9 159 ERK, Transactivation,
Cytoskeletal, MAPK,
JNK
Undetermined. Includes genes encoding molecules that
associate to the cytoskeleton (actin-related protein 2/3,
MAPK1, MAP3K1, RAB5A). Also present are T cell-expressed
genes (FAS, ITGA4/CD49D, ZNF1A1).
M 2.10 106 Myeloid,
Macrophage,
Dendritic,
Inflammatory,
Interleukin
Undetermined. Includes genes encoding for Immune-related
cell surface molecules (CD36, CD86, LILRB), cytokines (IL15)
and molecules involved in signaling pathways (FYB, TICAM2-
Toll-like receptor pathway).
M 2.11 176 Replication, Repress,
RAS,
Autophosphorylation,
Oncogenic
Undetermined. Includes kinases (UHMK1, CSNK1G1, CDK6,
WNK1, TAOK1, CALM2, PRKCI, ITPKB, SRPK2, STK17B,
DYRK2, PIK3R1, STK4, CLK4, PKN2) and RAS-family
members (G3BP, RAB14, RASA2, RAP2A, KRAS).
M 3.1 122 ISRE, Influenza,
Antiviral, IFN-gamma,
IFN-alpha, Interferon
Interferon-inducible. This set includes interferon-inducible
genes: antiviral molecules (OAS1/2/3/L, GBP1, G1P2,
EIF2AK2/PKR, MX1, PML), chemokines (CXCL10/IP-10),
signaling molecules (STAT1, STAt2, IRF7, ISGF3G).
M 3.2 322 TGF-beta, TNF,
Inflammatory,
Apoptotic,
Lipopolysaccharide
Inflammation I. Includes genes encoding molecules involved
in inflammatory processes (e.g., IL8, ICAM1, C5R1, CD44,
PLAUR, IL1A, CXCL16) and regulators of apoptosis (MCL1,
FOXO3A, RARA, BCL3/6/2A1, GADD45B).
M 3.3 276 Inflammatory,
Defense, Lysosomal,
Oxidative, LPS
Inflammation II. Includes genes encoding molecules inducing
or inducible by inflammation (IL18, ALOX5, ANPEP, AOAH,
HMOX1, SERPINB1), as well as lysosomal enzymes (PPT1,
CTSB/S, NEU1, ASAH1, LAMP2, CAST).
M 3.4 325 Ligase, Kinase, KIP1,
Ubiquitin, Chaperone
Undetermined. Includes genes encoding protein
phosphatases (PPP1R12A, PTPRC, PPP1CB, PPM1B) and
phosphoinositide 3-kinase (PI3K) family members (PIK3CA,
PIK32A, PIP5K3).
M 3.5 22 No keyword
extracted
Undetermined. Composed of only a small number of
transcripts. Includes hemoglobin genes (HBA1, HBA2, HBB).
M 3.6 288 Ribosomal, T cell,
Beta-catenin
Undetermined. This set includes genes encoding
mitochondrial ribosomal proteins (MRPLs, MRPs),
mitochondrial elongation factors (GFM1/2), Sortin Nexins
(SN1/6/14), as well as lysosomal ATPases (ATP6V1C/D).
M 3.7 301 Spliceosome,
Methylation,
Ubiquitin
Undetermined. Includes genes encoding proteasome
subunits (PSMA2/5, PSMB5/8); ubiquitin protein ligases HIP2,
STUB1, as well as components of ubiqutin ligase complexes
(SUGT1).
M 3.8 284 CDC, TCR, CREB,
Glycosylase
Undetermined. Includes genes encoding enzymes:
aminomethyltransferase, arginyltransferase, asparagines
synthetase, diacylglycerol kinase, inositol phosphatases,
methyltransferases, helicases.
M 3.9 260 Chromatin,
Checkpoint,
Replication,
Transactivation
Undetermined. Includes genes encoding kinases (IBTK,
PRKRIR, PRKDC, PRKCI) and phosphatases (e.g., PTPLB,
PPP2CB/3CB, PTPRC, MTM1, MTMR2).Immunity 29, 150–164, July 18, 2008 ª2008 Elsevier Inc. 153
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Modular Analysis Framework for Blood Genomicsor predominantly underexpressed. This observation is notable
because modules were not selected on the basis of differences
in expression between study groups but, instead, on clustering
patterns.
To graphically represent global transcriptional changes, spots
were aligned on a grid, with each position corresponding to a
different module (Figure 1A). Spot intensity positively correlates
with the proportion of differentially expressed transcripts,
Figure 1. Analysis of Patient Blood Leukocyte Transcriptional Profiles
(A) Module-level analysis. Gene-expression levels from PBMCs of patients with acute S. pneumoniae infection and healthy volunteers were compared (p < 0.05,
Mann-Whitney U test) in modules M1.3, M1.5, M1.8, and M3.2. Pie charts indicate the proportion of genes significantly changed for each module. Graphs
represent transcriptional profiles of genes that were significantly changed. Each line shows levels of expression (y axis) of a single transcript across multiple
conditions (samples, x axis). Expression is normalized to the median expression value of the control group. Results obtained for the 28 PBMC transcriptional
modules are displayed on a grid. Coordinates indicate module IDs (e.g., M2.8 is row M2, column 8). Spots indicate the proportion of genes significantly changed
for each module in patients with S. pneumoniae infection as compared to healthy controls. Red: overexpressed. Blue: underexpressed.
(B) Disease fingerprints. Three additional data sets were similarly processed. Profiles were obtained from patients with Systemic Lupus Erythematosus, liver-
transplant recipients under pharamacological immunosuppression infection, and patients with metastatic melanoma. Functional interpretation is indicated on
a grid by a color code. Detailed functional descriptions are provided in Table 1.154 Immunity 29, 150–164, July 18, 2008 ª2008 Elsevier Inc.
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Modular Analysis Framework for Blood Genomicswhereas spot color indicates the polarity of the change (red: over-
expressed, blue: underexpressed). The resulting map represents
molecular perturbations associated with a disease state. A blank
grid would indicate that no significant differences exist between
the disease and the healthy baseline. Conversely, the presence
of blue and red spots as in Figure 1A indicates that expression
levels of sets of transcripts are increased or decreased in patients
with acute S. pneumoniae infection as compared to healthy
controls. In addition, for the facilitation of data interpretation,
modules’ coordinates were associated to the functional cate-
gories that have been previously assigned (Figure 1B, Table 1).
For instance, Modules M1.3 and M2.1, respectively, associated
with B cells and cytotoxic cells and were underexpressed in the
S. aureus group as compared to the healthy group, whereas
modules M2.2 and M3.2, respectively, associated with neutro-
phils and inflammation and were overexpressed.
Thus, we showed that sets of transcriptional modules can be
used as a reference for the analysis and interpretation of data
generated independently from those used for module construc-
tion. Furthermore we have developed a means to visualize tran-
scriptional changes on a module-by-module basis, which in
conjunction with functional annotations yields an interpretable
representation of microarray results.
We next generated module maps for three additional groups of
patients (22 systemic lupus erythematosus patients [SLE], 16
metastatic melanoma patients, and 16 liver-transplant recipi-
ents), as well as their respective control groups, composed of
10 to 12 healthy donors who were matched for age and sex (Fig-
ure 1B, Table S2). Results for M1.1 and M1.2 alone distinguished
all four diseases (S. pneumoniae: M1.1 = no change, M1.2 = over-
expressed; SLE: M1.1 = overexpressed, M1.2 = no change;
melanoma: M1.1 = underexpressed, M1.2 = overexpressed;
transplant: M1.1 = underexpressed, M1.2 = underexpressed). A
number of genes in M3.2 (‘‘inflammation’’) were overexpressed
in patients with melanoma or S. pneumoniae infection, as well
as in transplant recipients, whereas genes in M3.1 (‘‘interferon-in-
ducible’’) were overexpressed inpatients withSLEand, toa lesser
extent, in transplant recipients. M2.1 and M2.8 include, respec-
tively, cytotoxic cell-related genes and T cell transcripts, which
are underexpressed in lymphopenic SLE patients and transplant
recipients treated with immunosuppressive drugs. Overall, al-
though these comparisons showed that modules can be shared
between diseases (e.g., underexpression for M1.3 transcripts in
both S. pneumoniae and melanoma groups), global modular
changes remained disease-specific.
Module maps provide a means to organize and reduce the
dimension of complex data and to thereby facilitate its interpreta-
tion. However useful it is, this oversimplified representation at the
same time lacks the depth that systems-scale analyses are able
to provide. Representing changes at the module level with a red
or blue spot, for instance, does not indicate which of the genes
are significantly changed. Indeed, a spot of the same color in
two different diseases might be attributed to two different sub-
sets of genes belonging to the same module. The disconnect be-
tween gene-level and module-level data is especially apparent
when the results are presented in a static format; i.e., on paper.
Thus, we have developed an interactive web interface allowing
users to switch seamlessly between module-level data and
gene-level data (Figure S3). Interactive module maps can beaccessed at www.biir.net/modules. In addition to the four data
sets analyzed in the context of this manuscript, we loaded on this
tool third-party data sets made publicly available by others (Burc-
zynski et al., 2006). Mapping transcriptional changes in patients
with Crohn’s disease and ulcerative colitis highlighted similarity
and differences between these diseases, with, for instance, a char-
acteristic overexpressionof transcripts linkedtoplasmacells (M1.1)
in ulcerative colitis. This repository will be updated as more blood
transcriptional data become available from our and other groups.
Using Modules as a Basis for the Discovery
of Blood Transcriptional Biomarkers
Microarray gene-expression data generated from blood not only
provide valuable insights into mechanisms of disease pathogen-
esis but also constitute a promising source of biomarkers. The
difficulty, however, lies in the extraction of indicators of potential
clinical value from the vast amounts of data generated. We used
modular transcriptional data as the foundation of our biomarker-
discovery strategy. This approach was implemented with the use
of a data set generated from patients with SLE.
Microarray analyses have been carried out on PBMCs ob-
tained from pediatric and adult SLE patients (Baechler et al.,
2003; Bennett et al., 2003; Crow et al., 2003; Kirou et al., 2004).
Using an earlier generation of Affymetrix arrays (12,600 probe
sets), we identified a type I interferon (IFN) signature in all pediat-
ric patients with active diseases (Bennett et al., 2003). This anal-
ysis also revealed the presence of neutrophil, immunoglobulin
(Ig), and lymphopenic signatures that correlated with the pres-
ence of low-density granulocytes, plasma cell precursors, and
a reduction in lymphocyte numbers in SLE blood, respectively
(Bennett et al., 2003).
These findings were confirmed in the present study, with signif-
icant changes observed in modules M3.1, M2.2, M1.1, and M2.8
(interferon-inducible, neutrophils, plasma cells, and T lympho-
cytes, respectively) for a new data set generated from a cohort
of 22 pediatric lupus patients sampled at the time of diagnosis
and before initiation of treatment, compared to healthy controls
(Figure 1B). Transcriptional changes were observed in seven
additional modules (M1.7, M2.1, M2.3, M2.4, M2.5, M2.6, and
M2.7). Two of these modules, M1.7 and M2.4, included tran-
scripts encoding ribosomal protein family members whose
expression was recently found to be altered in acute infection
and sepsis (Calvano et al., 2005; Thach et al., 2005). Furthermore,
our unpublished observations have shown that in vitro exposure
of purified human monocytes to interferon alpha results in a late
downregulation of the transcripts forming these modules. In addi-
tion, marked changes in gene expression were also observed for
modules M2.1 and M2.3, which include transcripts expressed in
cytotoxic cells and in erythrocytes, respectively. Interestingly, the
pattern of change in M2.1, M2.2, M2.3, and M2.4 within the SLE
group was well-conserved across diseases. Indeed, increased
expression for M2.2 and M2.3 and decreased expression for
M2.1 and M2.4 were also observed in transplant recipients, as
well as in patients with acute S. pneumoniae infections. This
partial convergence is likely to reflect the existence of core
transcriptional responses to disease or injury (e.g., inflammation).
The proposed biomarker-selection strategy relies on modules
for reducing highly dimensional microarray data sets in a stepwise
manner (Figure 2). Starting from the full set of 28 modules, onlyImmunity 29, 150–164, July 18, 2008 ª2008 Elsevier Inc. 155
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Modular Analysis Framework for Blood Genomicsthose for which a set minimum proportion of transcripts are
significantly changed between the study groups are selected
(Figure 2A; e.g., minimum proportion of differentially expressed
transcripts at p < 0.05 = 15% overexpressed or underexpressed
transcripts; in the example given, 11 SLE modules meet this crite-
rion). This eliminates from the selection pool the modules register-
ing fewerconsistent changes thatcouldbe attributed tonoise. The
cutoffs used for gene selection can be adjusted to adapt the
number of candidate markers that will be returned by this analysis.
We then generated composite values for each sample. The
arithmetic average of normalized expression values across sig-
nificantly overexpressed or underexpressed genes selected
from each module was calculated (Figure 2B). Each resulting
‘‘transcriptional vector’’ recapitulates the expression of a given
module (or a select set of genes within a module) in a given
patient. A spider graph connects all the vector values obtained
for each patient (Figure 2C). This is in contrast with the module
maps defined earlier, which display the frequency of significant
changes for an entire patient cohort module-by-module.
SLE Patient Profiles Are Linked to Disease Activity
Transcriptional vectors were derived for the entire cohort of 22
untreated pediatric SLE patients with the use of the set of 11
Figure 2. Module-Based Biomarker-Selec-
tion Strategy
Modules are used as a starting point for the gener-
ation of biomarker signatures and progressive
reduction of the dimension of microarray data:
(A) Mapping global transcriptional changes with
the use of a modular framework identified 11 mod-
ules for which at least 15% of the transcripts are
significantly changed between controls and
patients with SLE.
(B) Transcriptional vectors were generated by the
averaging of the normalized expression values of
differentially expressed transcripts for each one
of the 11 modules selected.
(C) Composite expression values are plotted as
vectors on a ‘‘spider graph.’’ Each line represents
a patient profile. Multivariate scores can be gener-
ated to recapitulate the changes registered by
several transcriptional vectors and monitor
changes in an individual patient over time.
SLE modules detailed above (the 628 dif-
ferentially expressed genes distributed
among those 11 vectors are listed in Table
S3). In Figure 3A, each line represents the
expression profile of one patient; the
thicker line shows the average expression
for the patients forming this group. The
values are normalized per gene with the
use of the median expression value of
healthy volunteers and are represented
on a logarithmic scale. Figure 3B displays
the expression pattern characteristic of
healthy volunteers. Differences between
the healthy group and the SLE group
were statistically significant for each of
the modules (p < 0.01; Mann-Whitney U test). Patient profiles
were also generated for an independent set of 31 children with
SLE treated with steroids and/or cytotoxic drugs and/or hydrox-
ychloroquine (Figure 3C, Table S4). Interestingly, average profiles
for both treated and untreated patient cohorts were almost super-
imposable (Figure 3D—no significant difference at p < 0.01; V2.2
p = 0.04; Mann-Whitney U test). However, patient selection in
both groups was such that they presented similar disease activity
as measured by the clinical index SLEDAI (SLE disease-activity
index: untreated patients average = 11.5 ± 7.9, treated patients
average = 9.4 ± 6.4; Student’s t test p = 0.3).
In order to investigate a possible link between SLE activity and
patient transcriptional profiles, we stratified samples solely on the
basis of SLEDAI scores. Samples from patients with mild disease
activity (SLEDAI [0–6]) presented a profile closer to that of healthy
subjects (Figure 3E) whereas patients with high disease activity
(SLEDAI [14-28]) presented an exacerbated profile (Figure 3F—
comparison of mild versus high disease activity: V1.7, V2.2, V2.3,
V2.4, V2.8, and V3.1: p < 0.01; V1.1 p = 0.07; V2.1 p = 0.06; V2.5
p = .8; V2.6 p = 0.02; V2.7 p = 0.08; Mann-Whitney U test).
These results suggest that composite transcriptional vectors
identified in SLE patients are associated with disease severity
and have potential value as biomarkers.156 Immunity 29, 150–164, July 18, 2008 ª2008 Elsevier Inc.
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as Indicators of SLE Disease Progression
SLE is a multisystemic disease presenting a wide range of clini-
cal and laboratorial abnormalities. Objectively assessing disease
activity across patients or longitudinally in individual patients can
therefore be challenging. At least six composite measures of SLE
global disease activity have been developed (Bae et al., 2001;
Bencivelli et al., 1992; Bombardier et al., 1992; Hay et al.,
1993; Liang et al., 1989; Petri et al., 1999) and have been used
to assess disease progression during clinical trials. These mea-
sures, however, rely on a series of clinical and laboratory findings
and are cumbersome to obtain. The SLEDAI, one of the simplest
measures, considers 24 different attributes that need to be ob-
tained at every clinic visit. Additionally, given the heterogeneous
nature of the clinical disease, not all SLE manifestations are com-
puted within these measures, making the overall assessment of
the patient sometimes difficult. Thus, establishment of an objec-
tive disease activity index would be beneficial. We assessed
Figure 3. SLE Transcriptional Vectors
(A–C) Composite transcriptional vectors identified
from a pediatric SLE patient population sampled
prior to the initiation of therapy. Each line on the
radar plot represents a patient profile (logarithmic
scale). Values are normalized per gene with the
use of the median expression value relating to
healthy volunteers. The thicker line represents
the average normalized expression profile for this
group of patients (A). Profiles were generated for
healthy volunteers (B) and an independent cohort
of pediatric SLE patients under treatment (C).
Green and orange colors indicate averaged nor-
malized expression profiles for treated (green)
and untreated (orange) SLE patient cohorts.
(D) Patient profiles were plotted on the same
vectors on the basis of clinical activity (SLEDAI),
regardless of treatment.
(E) Patients with low disease activity (SLEDAI
scores from 0 to 6).
(F) Patients with high disease activity (SLEDAI
scores from 14 to 28).
whether such activity index could be gen-
erated from blood leukocyte microarray
transcriptional data.
The analysis of pediatric SLE patient
profiles carried out above showed a link
between transcriptional vectors and
clinical disease manifestations. We have
previously found that expression of indi-
vidual genes or gene signatures (such
as interferon-inducible genes) could be
affected by treatment (Bennett et al.,
2003). Therefore, our aim was to maxi-
mize the number of transcriptional signa-
tures used as a basis for the generation
of a clinical indicator of disease activity.
We computed correlations between
composite expression values for individ-
ual dimensions (transcriptional vectors)
and the clinical-activity index (SLEDAI)
for each of the patients in our untreated cohort (Figure 4A). We
found that two dimensions (corresponding to V2.2 [‘‘neutrophil’’]
and V3.1[‘‘interferon-inducible’’] modules) correlated positively
with disease activity, whereas dimensions corresponding to
V1.7, V2.4, and V2.8 (‘‘ribosomal proteins’’ and ‘‘T cells’’) corre-
lated negatively. We then verified that differences in expression
observed for a selection of transcripts belonging to these five
modules could be confirmed with real-time PCR. Two transcripts
from M1.7, M2.2, M2.4, M2.8, and M3.1 were tested in ten
healthy controls and 25 patients. Differences in expression
were significant in nine out of the ten transcripts tested
(CCDC72, ELA2, MPO, FBL, EEF1D, IL23A, SIGLEC1 p <
0.001; GATA3, MX1 p < 0.05; GLTSCR2 p = 0.8). Only one of
the transcripts tested, GLTSCR2, did not display the expected
difference between control and SLE groups. This degree of
concordance is consistent with rates reported in the literature
(Bosotti et al., 2007). The discrepancy could be attributed to
differences in probe selection for the respective assays.Immunity 29, 150–164, July 18, 2008 ª2008 Elsevier Inc. 157
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Modular Analysis Framework for Blood GenomicsFigure 4. SLE Transcriptional Vectors Correlate with Disease Activity
(A) Expression profiles of genes forming vectors V1.7SLE, V2.2SLE, V2.4SLE, V2.8SLE, and V3.1SLE correlating with a clinical SLE disease-activity index (SLEDAI).
Graphs represent expression levels of individual transcripts forming each of the vectors in 12 healthy individuals and 22 untreated pediatric SLE patients. Average
expression values across transcripts forming each vector are shown on the graph in yellow. Correlations between averaged vector expression values and SLEDAI
scores are shown below (Spearman correlation).
(B) Multivariate scores were obtained for 22 untreated pediatric SLE patients by linear-regression analysis of multivariate transcriptional U scores (y axis) for
vectors V1.7SLE, V2.2SLE, V2.4SLE, V2.8SLE, V3.1 SLE, and SLEDAI (x axis). The light shaded area indicates the 95% confidence limits for individual predicted
values. The dark shaded area indicates the 95% confidence limits for the slope and intercept.
(C) The same analysis discussed in (B) was applied to 31 pediatric patients with SLE receiving different combinations of therapy.158 Immunity 29, 150–164, July 18, 2008 ª2008 Elsevier Inc.
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entially expressed transcripts were also significantly correlated
with microarray data (Figures S4 and S5).
A nonparametric method for analyzing multivariate ordinal
data was used to score the patients on the basis of these five
dimensions (Spangler et al., 2004; Wittkowski et al., 2004). The
advantage of this approach is that there is no need for additional
assumptions and validations. Once the available knowledge is
incorporated by the making of the initial transformations, the pro-
posed scores are valid by construction, as long as each variable
increases or decreases with the unobservable latent factor.
Thus, no empirical evaluation is needed. Because no assump-
tions are made regarding the functional form of the relationship,
U scores are scale-independent.
U-scores were obtained for all patients in the untreated cohort
(n = 22). A polarity of 1 was attributed to vectors correlating
positively with disease activity (i.e., Neutrophil: V2.2, Interferon:
V3.1). The polarity of vectors correlating inversely with disease
activity was set to 1 (T cells: V2.8 and Ribosomal proteins:
V1.7 and V2.4). This allowed the ranking of all patients within
this group. U scores have positive values (most-severe disease)
or negative values (less-severe disease), reflecting the rank of
each sample versus the other patients forming this cohort. The
association between the multivariate ‘‘transcriptional scores’’
and SLEDAI was assessed with linear regression and was deter-
mined to be statistically significant (Figure 4B; r = 0.83, df = 1,
t = 6.66, and p < .0001). The correlation achieved by this score
was superior to its individual components. Using the same pro-
cess, correlation between ‘‘transcriptional score’’ and SLEDAI
was examined for the treated cohort of pediatric patients with
SLE (n = 31) and was found to be statistically significant as
well (Figure 4C; r = 0.63, df = 1, t = 4.40, p = 0.0001).
Thus, distinct immunological signatures associated with the
pathogenesis of SLE have been reduced to a unique multivariate
score correlating with disease activity.
Multivariate Transcriptional Scores are Used to Monitor
Disease Progression in Patients with SLE
Lupus disease flares can lead to irreversible worsening of the
patient’s status. We tested the relevance of the multivariate tran-
scriptional score for longitudinal monitoring of the disease activ-
ity in a cohort of 20 pediatric SLE patients (two to four time
points/patient, intervals between each time point varied from
one month to 18 months). Half of the patients had been included
in our cross-sectional analysis before they were enrolled in this
longitudinal study.
During the follow-up period, the SLEDAI fluctuated in ten
patients and remained constant in the other ten (Figure 5). Parallel
trends were observed between transcriptional U scores and
SLEDAI longitudinal measures in a majority of patients. The pos-
itive association between SLEDAI and transcriptional scores was
verified statistically with the use of a linear-regression model.
The estimated model was: transcriptional score = 18.13 + 1.26
(SLEDAI) 0.03 (Days). The overall model was statistically signif-
icant (df = 1, chi sq. = 28.44, p < .0001), as was the association
between the SLEDAI scores and the transcriptional scores (df =
28, t = 2.41, p = 0.0229). For every one-unit increase in SLEDAI
score, the transcriptional score increases by 1.3. Overall, SLEDAI
index scores and transcriptional scores reflected similar activitiesaccording to their respective scales in all but six patients (SLE31,
SLE78, SLE125, SLE130, SLE135, and SLE99), in whom the tran-
scriptional U scores were disproportionately high as compared to
SLEDAI index scores (SLEDAI values are positive, whereas
multivariate U scores can be positive or negative). One of the
patients, with the highest discrepancy (SLE78), was diagnosed
during the follow-up period with a life-threatening complication
(pulmonary hypertension), which is not computed within the
SLEDAI. Thus, severity of disease was more accurately assessed
by the transcriptional score. Disease flaring and subsequent
recovery was detected in one patient (SLE31) during longitudinal
follow up with the use of both SLEDAI scores and transcriptional
score. Interestingly, however, not only does the amplitude of
change observed in the case of the transcriptional U score
appear to be much greater (0 to 40 versus 6 to 10 for SLEDAI),
but an increase could already be detected at the second time
point, two months before the worsening of this patient’s clinical
condition was detected by SLEDAI. Thus, these data illustrate
the potential value of microarray data and the multivariate tran-
scriptional scores derived from it for the longitudinal follow up
of disease progression in patients with complex multisystemic
diseases like SLE.
Composite Transcriptional Vectors Are Stable across
Laboratories and Microarray Platforms
To be truly viable as biomarkers, composite transcriptional
vectors must prove reliable. Early on, poor reproducibility of
microarray results obtained by different laboratories and across
platforms raised suspicion about the validity of these results,
and this remains a major concern (Bammler et al., 2005; Frantz,
2005; Ioannidis, 2005; Irizarry et al., 2005; Larkin et al., 2005;
Michiels et al., 2005; Shi et al., 2006). We compared transcrip-
tional profiles obtained with the use of two commercial microar-
ray platforms, Affymetrix and Illumina. PBMCs were isolated
from four healthy volunteers and ten liver-transplant recipients.
Starting from the same source of total RNA, we independently
generated targets and analyzed them with Affymetrix U133
GeneChips (at the Baylor Institute for Immunology Research)
and Illumina Human Ref8 BeadChips (at Illumina). Fundamental
differences exist between the two microarray technologies (see
Experimental Procedures for details). Probe IDs provided by
each manufacturer were converted into a common ID that was
used for matching gene-expression profiles. Overall, the Affyme-
trix and Illumina profiles for M3.1 appear to be similar (Figure 6).
However, correlations comparing both platforms performed for
individual genes forming M3.1 resulted in a median R2 value of
0.36 (ranging from 0.17 to 0.55) In other modules, such as M1.2
and M3.2, correlations observed at the level of individual genes
were also poor (R2 median [range] = 0.13 [0.02–0.5] for genes
forming M1.2 and 0.19 [0.06–0.4] for genes forming M3.2; Fig-
ure 6). In order to compare the overall modular expression pattern
across the two platforms, we derived for each module a compos-
ite transcriptional vector (averaging the values obtained for the
genes forming each module). Remarkably, the module-level ex-
pression values thus derived from Affymetrix and Illumina data
were highly comparable (Figure 6; transplant group Pearson
correlation coefficient R2 = 0.83, 0.98, and 0.93, for M1.2,
M3.1, and M3.2 respectively; p < 0.0001—in addition, R2 values
of M1.1 = 0.84, M1.3 = 0.95, M1.4 = 0.81, M1.5 = 0.74,Immunity 29, 150–164, July 18, 2008 ª2008 Elsevier Inc. 159
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Modular Analysis Framework for Blood GenomicsFigure 6. Cross-Microarray Platform Comparison
PBMC samples from healthy donors and liver-transplant recipients analyzed on two different microarray platforms: Affymetrix U133A&B GeneChips and Illumina
Sentrix Human Ref8 BeadChips. The same source of total RNA was used to independently prepare biotin-labeled cRNA targets. Expression is normalized to the
median of measurements obtained across all samples. Averaged expression values of the genes in each module are shown for both Affymetrix and Illumina
platforms.M1.8 = 0.62, M2.1 = 0.98, M2.2 = 0.82, M2.3 = 0.99, M2.6 = 0.73,
M2.8 =0.83, M2.10 = 0.66, M3.3 = 0.65, M3.8 = 0.57; R2 values for
other modules < 0.5). Taken together, these results indicate that
module-level composite expression data produce a more stable
metric than do individual gene-expression values, thereby en-
hancing data reproducibility across microarray platforms. This
property may be attributed to the stringent module-selection pro-
cess (transcripts must be coexpressed across many samples)
and to the fact that composite expression values are derived
from multiple measurements (smoothing the imprecision ob-
served at the level of individual probes).
DISCUSSION
Patient blood transcriptional profiling studies generate large-
scale data that are difficult to exploit. Adopting a module-based
data-mining strategy can facilitate biomarker and biological
knowledge discovery by focusing the analysis of microarray
data on stable sets of transcripts selected on the basis of their
clustering pattern across diseases.The module-construction strategy that we have designed
takes advantage of the biological variability inherent to patient-
based studies in order to identify the major transcriptional com-
ponents of this system. A clustering algorithm teases apart the
patterns emerging from the blood profiles obtained for different
diseases. Once patterns have been identified for each disease,
the cluster membership of individual transcripts is compared.
A module is formed of transcripts found to always belong to
the same clusters across all diseases (eight out of eight in our
example). The stringency of this requirement is progressively re-
laxed during the subsequent rounds of selection so that modules
are formed when transcripts fall in the same clusters in any com-
bination of seven diseases (round 2) or of six diseases (round 3).
This stepwise reduction of the stringency of filtering criteria
accounts for the fact that transcripts may not be ‘‘turned on’’ in
all diseases. Indeed, modules linked to interferon or to inflamma-
tion (M3.1 and M3.2) were, for instance, not formed until the third
round of selection. The validity of the transcriptional modules
thus generated was verified by different approaches. Random
permutations attested to the statistical validity of the module
construction, and coexpression was confirmed in independentFigure 5. Longitudinal Disease Monitoring with a Multivariate Disease-Activity Score
SLEDAI index (blue, right y axis) and transcriptional U scores (red, left y axis) of pediatric patients (identified by an SLE ID) over time (x axis). Time elapsed between
sampling is indicated in months.Immunity 29, 150–164, July 18, 2008 ª2008 Elsevier Inc. 161
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tients withS. pneumoniae infection who were not used to identify
modules) across laboratories and microarray platforms (Affyme-
trix versus Illumina). Furthermore, as should be expected of tran-
scriptional modules, literature profiling of genes forming each of
the modules revealed significant functional convergence, with
half of the modules associated with clearly identifiable functional
themes.
With the inclusion of profiles from a wide range of diseases,
our goal was to identify a ‘‘universal’’ set of modules that could
be used as a stable framework for subsequent analysis of any
PBMC data set. However, we anticipate that adding more dis-
eases to the selection pool will result in a refined partitioning of
the modules already identified and will add modules to the exist-
ing set. Also, although the collection of genome-wide PBMC
transcriptional profiles used for module selection is already ex-
tensive, the identification of a definitive module set will require
expanding the scale of this analysis.
Reducing the dimension of microarray data makes it more
amenable to interpretation. When confronted with such an over-
whelming amount of information, it is necessary to reduce it to
a manageable number of variables and to use visualization
schemes as a means to facilitate the identification of patterns
in the data, especially when performing comparisons across
diseases. Furthermore, after functional interpretation, we found
that the modules identified are linked to the two components
driving differential gene expression in blood: changes in relative
cellular abundance (e.g., B cell, cytotoxic cell modules) and in
gene regulation (e.g., inflammation, interferon). Thus, overlaying
these functional annotations to the fixed module patterns further
supports the interpretation of disease fingerprints. Inevitably,
however, reducing microarray data to a small set of variables
and broad functional categories can only offer an oversimplified
view of the data, and interactive mining tools are therefore
necessary to restore the unique depth perspective that sys-
tems-scale data are able to provide.
We have also explored the use of transcriptional modules as
a basis for biomarker discovery. By construction, modules in-
clude only transcripts which coclustered in at least six out of eight
diseases across many samples. The probability of this happening
just by chance is very low. In fact, when we ran tests in which gene
labels were permuted randomly in the different diseases, we
could not identify any modules. Also, the use of sets of transcrip-
tional modules as a basis for biomarker discovery should help
researchers focus on biologically relevant transcripts. Another
potential benefit of using modules as a framework for biomarker
discovery is that it allows the reduction of the dimension of micro-
array data. Identifying a small set of clinically valuable markers
from tens of thousands of candidates in a single analysis step is
a considerable challenge; noise is, again, a major issue. However,
when the data are reduced from over 44,000 variables to about
5000 distributed in 28 modules, biomarker discovery becomes
a much more manageable proposition. In the case of SLE,
comparisons carried out on a module-by-module basis identified
11 submodules with a minimum of 15% of transcripts overex-
pressed or underexpressed as compared to those of healthy
volunteers. Once the data are reduced to 11 composite values
(or transcriptional vectors), it then becomes possible to summa-
rize the results as one single multivariate score. Repeating mea-162 Immunity 29, 150–164, July 18, 2008 ª2008 Elsevier Inc.surements for multiple transcripts sharing the same pattern
within a module also makes for a more robust measurement,
which explains, at least in part, the level of correlation measured
between data generated on two microarray platforms in two inde-
pendent laboratories. Finally, the fact that some of the modules
can be associated to well-recognized biological pathways linked
to disease pathogenesis will help in further asserting the credibil-
ity of biomarkers derived from such analysis.
Indeed, upon being identified, SLE vectors were validated in
an independent set of samples. Furthermore, multivariate-result-
ing transcriptional scores were correlated to clinical disease-
activity indices in both cross-sectional and longitudinal sets of
samples. Our data demonstrate that composite transcriptional
vectors can be directly correlated to clinical disease activity in
patients with lupus.
In conclusion, the modular-analysis framework that we have
generated could prove useful for the discovery of diagnostic or
prognostic markers and provide the means for monitoring
disease progression and response to treatment in other com-
plex-disease settings.
EXPERIMENTAL PROCEDURES
Patient Information
Subjects were recruited at the Baylor University Medical Center of Dallas, the
Texas Scottish Rite Hospital, and the Children’s Medical Center of Dallas. The
study was approved by the Institutional Review Boards of UT Southwestern
Medical Center, Texas Scottish Rite Hospital, and Baylor Health Care System,
and informed consent was obtained from all patients (legal representatives
and patients over 10 yr of age). Bacterial and viral infections were confirmed
by standard bacterial cultures, direct fluorescent antigen testing, and viral
cultures. Patients with infections were recruited once a confirmed microbio-
logic diagnosis was established. The clinical and demographic characteristics
of SLE patients are summarized in Table S4.
Processing of Blood Samples
Blood samples were collected in acid citrate dextrose or EDTA tubes
(BD Vacutainer) and immediately delivered at room temperature to the Baylor
Institute for Immunology Research, Dallas, TX, for processing. PBMCs were
isolated via Ficoll gradient and immediately lysed in RLT reagent (QIAGEN,
Valencia, CA) with beta-mercaptoethanol (BME) and stored at –80C prior to
the RNA-extraction step.
Microarray Analysis
Total RNA was isolated with the RNeasy kit (QIAGEN) according to the manu-
facturer’s instructions, and RNA integrity was assessed with an Agilent 2100
Bioanalyzer (Agilent, Palo Alto, CA).
Affymetrix GeneChips
Target labeling was performed according to the manufacturer’s standard pro-
tocol (Affymetrix, Santa Clara, CA). Biotinylated cRNA targets were purified
and subsequently hybridized to Affymetrix HG-U133A and U133B GeneChips
(> 44,000 probe sets). Arrays were scanned with an Affymetrix confocal laser
scanner. Microarray Suite, Version 5.0 (MAS 5.0; Affymetrix) software was
used to assess fluorescent hybridization signals, to normalize signals, and to
evaluate signal-detection calls. Normalization of signal values per chip was
achieved with the MAS 5.0 global method of scaling to the target intensity
value of 500 per GeneChip. A gene-expression analysis software program,
GeneSpring, Version 7.1 (Agilent), was used to perform statistical analysis
and clustering.
Illumina BeadChips
Samples were processed and data were acquired by Illumina (San Diego, CA).
Targets were prepared with the Illumina RNA amplification kit (Ambion, Austin,
TX). cRNA targets were hybridized to Sentrix HumanRef8 BeadChips (> 25,000
probes), which were scanned on an Illumina BeadStation 500. Illumina’s
Immunity
Modular Analysis Framework for Blood GenomicsBeadstudio software was used for assessment of fluorescent hybridization
signals.
Quantitative Real-Time PCR
Biotinylated cRNA prepared for microarray analysis was reverse transcribed
into cDNA with the High-Capacity cDNA Reverse Transcription Kits (Applied
Biosystems, Foster City, CA). Real-time PCR was set up with Roche Probes
Master reagents and Universal Probe Library hydrolysis probes. PCR reaction
was performed on the LightCycler 480 (Roche Applied Science). Secondary
derivative calculation data were collected, and cross point values of target
genes were normalized to two housekeeping genes (ARHGDIB and GUSB).
Module-Construction Algorithm
Our goal was to extract from an extensive leukocyte microarray data set
groups of coordinately expressed transcripts spanning multiple diseases
(i.e., identifying genes in which expression is correlated across multiple
samples). Although the initial steps of our approach produce clusters of coor-
dinately transcribed genes in a manner similar to other groups, we refine the
process by generating modules based on cluster membership across multiple
independent microarray experiments: (1) Parallel analyses were performed,
grouping transcripts for eight different disease data sets with the K-means
clustering algorithm. (2) Transcripts that are coexpressed in the context of
several diseases were then identified (i.e., we examined cluster membership
across multiple independent microarray experiments). Also, in the first round
of selection, we started by choosing transcripts with shared cluster member-
ship for all eight diseases. For the subsequent round of selection, we ac-
counted for the fact that the different diseases might produce different pat-
terns; thus, we decreased the level of stringency accordingly (i.e., allowing
for one or even two diseases to be dropped in the second and the third rounds
of selection, respectively). In summary, this approach relies on the K-means
clustering algorithm and is tailored to capture transcriptional modules
spanning multiple diseases, starting with a large number of transcripts. This
module-construction algorithm is described in detail in the Supplementary
Experimental Procedures.
Multivariate U Scores
The detailed explanation of this method has been published recently (Wittkow-
ski et al., 2004), and the required tools are available at http://Mustat.
Rockefeller.edu. In brief, scores were obtained by computation of the average
normalized expression levels for all transcripts within the modules that were
identified as differentially expressed in SLE PBMCs.
Literature Profiling
The literature profiling algorithm employed in this study has been previously
described in detail (Chaussabel and Sher, 2002). This approach links genes
sharing similar keywords. It uses hierarchical clustering to analyze patterns
of term occurrence in literature abstracts.
Association between SLEDAI Scores and Multivariate U Scores
Linear regression was used in the cross-sectional analyses for assessment of
the association between the multivariate ‘‘transcriptional scores’’ and SLEDAI
scores for the treated and untreated pediatric SLE patients. Results and
figures were obtained with JMP statistical software (Version 7; SAS Institute).
When this association was assessed for the corresponding longitudinal data,
a linear mixed-effect model with a random intercept was used to account for
the repeated and unequally spaced observations. This modeling technique
is well described in such texts as Verbeke and Molenberghs (Verbeke and
Molenberghs, 2000) and Fitzmaurice et al. (Fitzmaurice et al., 2004). SAS
statistical software (Version 9.1; SAS Institute) was used for this portion of
the analysis.
ACCESSION NUMBERS
The microarray data used in this study have been deposited in NCBI’s Gene
Expression Omnibus (GEO) with the accession number GSE11907.SUPPLEMENTAL DATA
Supplemental data include supplemental experimental procedures, five fig-
ures, and five tables and can be found online at http://www.immunity.com/
cgi/content/full/29/1/150/DC1/.
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